We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma.
- Authors
Wilkinson, Mary J.; Frye, John W.; Small, Eric J.; Venook, Alan P.; Carroll, Peter R.; Ernest, Mary Lou; Stagg, Robert J.; Wilkinson, M J; Frye, J W; Small, E J; Venook, A P; Carroll, P R; Ernest, M L; Stagg, R J
- Abstract
<bold>Background: </bold>Twenty-nine patients with metastatic renal cell carcinoma (RCC) were treated with constant-infusion floxuridine (FUdR, Roche Laboratories, Nutley, NJ).<bold>Methods: </bold>The initial dosage was 0.075 mg/kg/day for 14 days every 28 days and was increased or decreased by 0.025-mg/kg/day increments at each subsequent cycle until the maximum tolerated dose (MTD) was achieved.<bold>Results: </bold>All patients were fully assessable. One (4%) patient had a complete response, 5 (17%) had a partial response, 13 (50%) had stabilized disease, and 10 (34%) had progressive disease. The treatment-limiting toxic effect was diarrhea, and the median tolerated dosage was 0.1 mg/kg/day for 14 days every 28 days (range, 0.05-0.275 mg/kg/day). Five of the six responses occurred at a dosage of 0.1 mg/kg/day or less, which was achievable in most patients. Patients who reached their MTD without achieving a complete or partial response were switched to circadian-infusion floxuridine to determine whether an increased dose intensity could be administered and whether this would translate into additional responses. A higher median tolerated dosage of 0.15 mg/kg/day was achieved with circadian administration; however, no additional responses were observed. The median survival time was 891 days after the diagnosis of metastatic RCC and 445 days after the institution of floxuridine therapy.<bold>Conclusions: </bold>Constant-infusion floxuridine is active against metastatic RCC and produces a response rate that appears to be comparable to that of circadian administration of floxuridine.
- Publication
Cancer (0008543X), 1993, Vol 71, Issue 11, p3601
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/1097-0142(19930601)71:11<3601::AID-CNCR2820711122>3.0.CO;2-#